[go: up one dir, main page]

AR126112A1 - Moléculas de unión a gpc3 - Google Patents

Moléculas de unión a gpc3

Info

Publication number
AR126112A1
AR126112A1 ARP220101525A ARP220101525A AR126112A1 AR 126112 A1 AR126112 A1 AR 126112A1 AR P220101525 A ARP220101525 A AR P220101525A AR P220101525 A ARP220101525 A AR P220101525A AR 126112 A1 AR126112 A1 AR 126112A1
Authority
AR
Argentina
Prior art keywords
sec
numbers
domain
ident
cancer
Prior art date
Application number
ARP220101525A
Other languages
English (en)
Inventor
Matthew Drever
Gabrielle M Romain
Sarah K Wyman
Chi Ying
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of AR126112A1 publication Critical patent/AR126112A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

Se proporcionan anticuerpos, fragmentos de estos, receptores de antígenos quiméricos (CAR) y receptores de células T (TCR) que comprenden uno o más de los dominios de unión a GPC3 descritos en la presente descripción. Se proporcionan composiciones, células y terapias celulares que comprenden los mismos. Además, se proporcionan además métodos de tratamiento. Reivindicación 1: Un anticuerpo, o fragmento de fijación al antígeno de este, que comprende un dominio de unión GPC3, en donde el dominio de unión a GPC3 comprende secuencias de tres regiones determinantes de complementariedad de cadena pesada (HCDR) de la región variable de cadena pesada (HCVR) de la sec. con núm. de ident.: 3, y secuencias de tres CDR de cadena ligera (LCDR) de la región variable de cadena ligera (LCVR) de la sec. con núm. de ident.: 14. Reivindicación 2: El anticuerpo, o fragmento de unión al antígeno de este de la reivindicación 1, en donde el dominio de unión de dominio de unión a GPC3 comprende un primer dominio que comprende tres regiones determinantes de complementariedad de cadena pesada (HCDR1, HCDR2 y HCDR3) y un segundo dominio que comprende tres regiones determinantes de complementariedad de cadena ligera (LCDR1, LCDR2 y LCDR3), en donde (i) la HCDR1 tiene una secuencia de acuerdo con una cualquiera de las sec. con núms. de ident.: 5 - 7; (ii) la HCDR2 tiene una secuencia de acuerdo con una cualquiera de las sec. con núms. de ident.: 8 - 10; (iii) la HCDR3 tiene una secuencia de acuerdo con una cualquiera de las sec. con núms. de ident.: 11 - 13; (iv) la LCDR1tiene una secuencia de acuerdo con una cualquiera de las sec. con núms. de ident.: 16 - 18; (v) la LCDR2 tiene una secuencia de acuerdo con una cualquiera de las sec. con núms. de ident.: 19 - 21; y (vi) la LCDR3 tiene una secuencia de acuerdo con una cualquiera de las sec. con núms. de ident.: 22 - 24. Reivindicación 3: El anticuerpo, o fragmento de unión al antígeno de este de una cualquiera de las reivindicaciones 1 - 2, en donde el anticuerpo, o fragmento de unión al antígeno de este comprende un primer dominio que comprende tres regiones determinantes de complementariedad de cadena pesada (HCDR) y un segundo dominio que comprende tres regiones determinantes de complementariedad de cadena ligera (LCDR), en donde: las HCDR y LCDR comprenden: (i) una HCDR1 de acuerdo con cualquiera de las sec. con núms. de ident.: 5 - 7; una HCDR2 de acuerdo con cualquiera de las sec. con núms. de ident.: 8 - 10; una HCDR3 de acuerdo con una cualquiera de las sec. con núms. de ident.: 11-13; una LCDR1 de acuerdo con cualquiera de las sec. con núms. de ident.: 16 - 18; una LCDR2 de acuerdo con cualquiera de las sec. con núms. de ident.: 19 - 21; una LCDR3 de acuerdo con una cualquiera de las sec. con núms. de ident.: 22 - 24. Reivindicación 4: El anticuerpo, o fragmento de unión al antígeno de este de una cualquiera de las reivindicaciones 1 - 3, en donde el anticuerpo, o fragmento de unión al antígeno de este comprende un primer dominio variable de cadena pesada que comprende las tres HCDR y un dominio variable de cadena ligera que comprende las tres LCDR, en donde: (i) el dominio variable de cadena pesada es al menos 80% idéntico a la sec. con núm. de ident.: 3, sec. con núm. de ident.: 27, sec. con núm. de ident.: 33, sec. con núm. de ident.: 39, o la sec. con núm. de ident.: 45; y (ii) el dominio variable de cadena ligera es al menos 80% idéntico a la sec. con núm. de ident.: 14, sec. con núm. de ident.: 29, sec. con núm. de ident.: 35, sec. con núm. de ident.: 41, o sec. con núm. de ident.: 47. Reivindicación 21: El método de la reivindicación 20, donde la enfermedad es carcinoma hepatocelular, carcinoma de células escamosas del pulmón, cáncer de esófago (adenocarcinoma de células escamosas), cáncer de cabeza y cuello, cáncer gástrico, melanoma, mesotelioma, cáncer de cuello uterino, cáncer de ovario, cáncer de mama, cáncer testicular, colangiocarcinoma, cáncer de colon, liposarcoma, schwannoma, o cualquier combinación de estos. Reivindicación 22: Un método para inducir una respuesta inmunitaria en un sujeto o para inmunizar a un sujeto contra carcinoma hepatocelular, el método comprende administrar al sujeto la célula T y/o la célula NK de la reivindicación 18 o la composición farmacéutica de la reivindicación 19 al paciente.
ARP220101525A 2021-06-08 2022-06-08 Moléculas de unión a gpc3 AR126112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163208274P 2021-06-08 2021-06-08

Publications (1)

Publication Number Publication Date
AR126112A1 true AR126112A1 (es) 2023-09-13

Family

ID=82482840

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101525A AR126112A1 (es) 2021-06-08 2022-06-08 Moléculas de unión a gpc3

Country Status (8)

Country Link
EP (1) EP4352102A1 (es)
KR (1) KR20240019811A (es)
CN (1) CN117730100A (es)
AR (1) AR126112A1 (es)
AU (1) AU2022291365A1 (es)
CO (1) CO2024000024A2 (es)
TW (2) TWI849430B (es)
WO (1) WO2022261061A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250819A1 (en) 2024-05-31 2025-12-04 Kite Pharma, Inc. Tricistronic constructs for anti-gpc3 car

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2013008376A (es) 2011-01-18 2013-08-12 Univ Pennsylvania Composiciones y metodos para el tratamiento de cancer.
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
MX2014003176A (es) 2011-09-16 2015-08-05 Univ Pennsylvania Celulas t diseñadas mediante arn para el tratamiento de cancer.
US9409994B2 (en) * 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
MX2016015162A (es) * 2014-05-22 2017-03-03 Genentech Inc Anticuerpos anti - gpc3 e inmunoconjugados.
WO2017196847A1 (en) * 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
CN110177876B (zh) * 2017-01-10 2023-03-31 国立大学法人山口大学 抗gpc3抗体
WO2018200586A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
US11802163B2 (en) * 2017-11-10 2023-10-31 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting glypican-3 or mesothelin
WO2020190217A2 (en) * 2019-03-21 2020-09-24 Agency For Science, Technology And Research Composition
CN113227148B (zh) * 2019-12-05 2022-11-01 上海翰森生物医药科技有限公司 抗gpc3抗体、其抗原结合片段及其医药用途

Also Published As

Publication number Publication date
KR20240019811A (ko) 2024-02-14
TWI887005B (zh) 2025-06-11
US20230020993A1 (en) 2023-01-19
TW202504928A (zh) 2025-02-01
EP4352102A1 (en) 2024-04-17
CN117730100A (zh) 2024-03-19
TW202313687A (zh) 2023-04-01
WO2022261061A1 (en) 2022-12-15
CO2024000024A2 (es) 2024-01-25
TWI849430B (zh) 2024-07-21
AU2022291365A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
JP2020528750A5 (es)
RU2019104980A (ru) Анти-icos антитела
HRP20250666T1 (hr) Anti-pro/latentna miostatinska protutijela i njihove uporabe
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
RU2015118180A (ru) Антитела к бета-амилоиду
RU2016138744A (ru) Антитела, фармацевтические композиции и их применения
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
AR121858A1 (es) Anticuerpo anti-ox40 y usos del mismo
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха
HRP20220197T1 (hr) Antitijela protiv il-22r
RU2016141285A (ru) Биспецифические антигенсвязывающие полипептиды
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
JP2017511152A5 (es)
AR126112A1 (es) Moléculas de unión a gpc3
PE20240809A1 (es) Composiciones y metodos de los anticuerpos anti-pacap
JPWO2020227457A5 (es)
AR131528A1 (es) Anticuerpos anti-b7h3 y métodos de uso
AR133022A1 (es) Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco
AR104368A1 (es) Anticuerpos biespecíficos anti-cd20- / anti-baff
AR130865A1 (es) Agentes de unión de msln y cd3 y métodos de uso de estos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal